These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 21911148)

  • 1. A retrospective 12-month study of conversion to everolimus in lung transplant recipients.
    Roman A; Ussetti P; Zurbano F; Borro JM; Solé A; Carreño MC; Santos F
    Transplant Proc; 2011 Sep; 43(7):2693-8. PubMed ID: 21911148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
    Stephany BR; Boumitri M; Budev M; Alao B; Poggio ED
    J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus in lung transplantation in Chile.
    Parada MT; Alba A; Sepúlveda C
    Transplant Proc; 2010; 42(1):328-30. PubMed ID: 20172343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term use of everolimus in lung transplant patients.
    Parada MT; Alba A; Sepúlveda C; Melo J
    Transplant Proc; 2011; 43(6):2313-5. PubMed ID: 21839261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up.
    Rothenburger M; Teerling E; Bruch C; Lehmkuhl H; Suwelack B; Bara C; Wichter T; Hinder F; Schmid C; Stypmann J
    J Heart Lung Transplant; 2007 Mar; 26(3):250-7. PubMed ID: 17346627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
    Cataneo-Dávila A; Zúñiga-Varga J; Correa-Rotter R; Alberú J
    Transplant Proc; 2009 Dec; 41(10):4138-46. PubMed ID: 20005355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P; Metselaar HJ; Fischer L; Dumortier J; Boudjema K; Hardwigsen J; Rostaing L; De Carlis L; Saliba F; Nevens F
    Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.
    Gullestad L; Iversen M; Mortensen SA; Eiskjaer H; Riise GC; Mared L; Bjørtuft O; Ekmehag B; Jansson K; Simonsen S; Gude E; Rundqvist B; Fagertun HE; Solbu D; Bergh CH
    Transplantation; 2010 Apr; 89(7):864-72. PubMed ID: 20061999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion from cyclosporine to tacrolimus stabilizes the course of lung function in lung transplant recipients with bronchiolitis obliterans syndrome.
    Borro JM; Bravo C; Solé A; Usetti P; Zurbano F; Lama R; De la Torre M; Román A; Pastor A; Laporta R; Cifrián JM; Santos F
    Transplant Proc; 2007 Sep; 39(7):2416-9. PubMed ID: 17889206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.
    Holdaas H; Rostaing L; Serón D; Cole E; Chapman J; Fellstrøm B; Strom EH; Jardine A; Midtvedt K; Machein U; Ulbricht B; Karpov A; O'Connell PJ;
    Transplantation; 2011 Aug; 92(4):410-8. PubMed ID: 21697773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate.
    Arora S; Gude E; Sigurdardottir V; Mortensen SA; Eiskjær H; Riise G; Mared L; Bjørtuft O; Ekmehag B; Jansson K; Simonsen S; Aukrust P; Solbu D; Iversen M; Gullestad L
    J Heart Lung Transplant; 2012 Mar; 31(3):259-65. PubMed ID: 22333403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion from sirolimus to everolimus in kidney transplant recipients receiving a calcineurin-free regimen.
    Carvalho C; Coentrão L; Bustorff M; Patrício E; Sampaio S; Santos J; Oliveira G; Pestana M
    Clin Transplant; 2011; 25(4):E401-5. PubMed ID: 21457330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion to everolimus in kidney transplant recipients: a safe and simple procedure.
    Ruiz JC; Sanchez-Fructuoso A; Rodrigo E; Conesa J; Cotorruelo JG; Gómez-Alamillo C; Calvo N; Barrientos A; Arias M
    Transplant Proc; 2006 Oct; 38(8):2424-6. PubMed ID: 17097956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients--a case series.
    Lovric S; Kielstein JT; Kayser D; Bröcker V; Becker JU; Hiss M; Schiffer M; Sommerwerck U; Haller H; Strüber M; Welte T; Gottlieb J
    Nephrol Dial Transplant; 2011 Sep; 26(9):3032-8. PubMed ID: 21310739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
    Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E
    Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus in clinical practice in long-term liver transplantation: an observational study.
    Casanovas T; Argudo A; Peña-Cala MC
    Transplant Proc; 2011; 43(6):2216-9. PubMed ID: 21839237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis.
    Saliba F; Dharancy S; Lorho R; Conti F; Radenne S; Neau-Cransac M; Hurtova M; Hardwigsen J; Calmus Y; Dumortier J
    Liver Transpl; 2011 Aug; 17(8):905-13. PubMed ID: 21384525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients.
    Schweiger M; Wasler A; Prenner G; Stiegler P; Stadlbauer V; Schwarz M; Tscheliessnigg K
    Transpl Immunol; 2006 Jun; 16(1):46-51. PubMed ID: 16701176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal function improvement after conversion to proliferation signal inhibitors during long-term follow-up in heart transplant recipients.
    Kaplinsky E; González-Costello J; Manito N; Roca J; Barbosa MJ; Nebot M; Salazar-Mendiguchia J; Berdejo J; Mañas P; Miralles A; Cequier A
    Transplant Proc; 2012 Nov; 44(9):2564-6. PubMed ID: 23146455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of the conversion to everolimus in renal transplant recipients with posttransplantation malignancies.
    Chiurchiu C; Carreño CA; Schiavelli R; Petrone H; Balaguer C; Trimarchi H; Pujol GS; Novoa P; Acosta F; González C; Arriola M; Massari PU;
    Transplant Proc; 2010; 42(1):277-9. PubMed ID: 20172329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.